Drug Name:Abciximab
Drug Class:Glycoprotein IIb/IIIa inhibitor
Mechanism of Action:Blocks the platelet glycoprotein IIb/IIIa receptor, preventing platelet aggregation
Use:Prevention of ischemic complications in patients undergoing percutaneous coronary intervention (PCI)
Side Effects:
  • Bleeding
  • Thrombocytopenia
  • Hypotension
Contraindications:Active internal bleeding, recent major surgery, history of stroke within 30 days
Specialty:
  • Cardiology
  • Interventional Cardiology